Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

logo del sistema bibliotecario dell'ateneo di padova

Hajman, Karla (2007) Influence of protein synthesis regulation on chemoresistance in cancer cells. [Laurea specialistica biennale]

Per questo documento il full-text online non è disponibile.

Abstract

Questo lavoro si concentra sulla regolazione e il ruolo della sintesi proteica nella resistenza agli analoghi pirimidinici nelle cellule del cancro alla vescica.

Item Type:Laurea specialistica biennale
Corsi di Laurea specialistica biennale:Facoltà di Scienze MM. FF. NN. > Biotecnologie industriali
Uncontrolled Keywords:Protein synthesis Gemcitabine DNA damage
Subjects:Area 06 - Scienze mediche > MED/04 Patologia generale
Codice ID:14051
Relatore:Papini, Emanuele
Data della tesi:2007
Biblioteca:Polo di Scienze > CIS "A. Vallisneri" - Biblioteca Biologico Medica
Note per la fruizione:L'AUTORE HA CHIESTO LA RIMOZIONE DEL FULL TEXT DELLA TESI PER MOTIVI PERSONALI
Tesi sperimentale (Si) o compilativa (No)?:No

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione e non da noi.

Jemal, A. et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004). Cerca con Google

Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348 (2001). Cerca con Google

Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). Cerca con Google

Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995). Cerca con Google

Hayflick, L. Mortality and immortality at the cellular level. A review. Biochemistry (Mosc. ) 62, 1180-1190 (1997). Cerca con Google

Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994). Cerca con Google

Morin, G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59, 521-529 (1989). Cerca con Google

Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971). Cerca con Google

Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996). Cerca con Google

Hamburger, A. W. & Salmon, S. E. Primary bioassay of human tumor stem cells. Science 197, 461-463 (1977). Cerca con Google

Varner, J. A. & Cheresh, D. A. Integrins and cancer. Curr. Opin. Cell Biol. 8, 724-730 (1996). Cerca con Google

Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002). Cerca con Google

Zhou, B. P. et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 275, 8027-8031 (2000). Cerca con Google

Seth, A., Gonzalez, F. A., Gupta, S., Raden, D. L. & Davis, R. J. Signal transduction within the nucleus by mitogen-activated protein kinase. J. Biol. Chem. 267, 24796-24804 (1992). Cerca con Google

Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004). Cerca con Google

Graus-Porta, D., Beerli, R. R., Daly, J. M. & Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (1997). Cerca con Google

Sherr, C. J. Principles of tumor suppression. Cell 116, 235-246 (2004). Cerca con Google

Lee, W. H. et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235, 1394-1399 (1987). Cerca con Google

Harbour, J. W. & Dean, D. C. Rb function in cell-cycle regulation and apoptosis. Nat. Cell Biol. 2, E65-E67 (2000). Cerca con Google

Lane, D. P., Lu, X., Hupp, T. & Hall, P. A. The role of the p53 protein in the apoptotic response. Philos. Trans. R. Soc. Lond B Biol. Sci. 345, 277-280 (1994). Cerca con Google

Friedberg, E. C. DNA damage and repair. Nature 421, 436-440 (2003). Cerca con Google

Zhou, J. & Giannakakou, P. Targeting microtubules for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents 5, 65-71 (2005). Cerca con Google

Fischer, O. M., Streit, S., Hart, S. & Ullrich, A. Beyond Herceptin and Gleevec. Curr. Opin. Chem. Biol. 7, 490-495 (2003). Cerca con Google

Hoption Cann, S. A., van Netten, J. P. & van, N. C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad. Med. J. 79, 672-680 (2003). Cerca con Google

Bohle, A. & Brandau, S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol. 170, 964-969 (2003). Cerca con Google

Roos, W. P. & Kaina, B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 12, 440-450 (2006). Cerca con Google

Zhou, B. B. & Elledge, S. J. The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439 (2000). Cerca con Google

Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis. Science 274, 1664-1672 (1996). Cerca con Google

Cha, R. S. & Kleckner, N. ATR homolog Mec1 promotes fork progression, thus averting breaks in replication slow zones. Science 297, 602-606 (2002). Cerca con Google

Sogo, J. M., Lopes, M. & Foiani, M. Fork reversal and ssDNA accumulation at stalled replication forks owing to checkpoint defects. Science 297, 599-602 (2002). Cerca con Google

Brown, E. J. & Baltimore, D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 17, 615-628 (2003). Cerca con Google

Zachos, G., Rainey, M. D. & Gillespie, D. A. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. 22, 713-723 (2003). Cerca con Google

Kim, S. T., Lim, D. S., Canman, C. E. & Kastan, M. B. Substrate specificities and identification of putative substrates of ATM kinase family members. J. Biol. Chem. 274, 37538-37543 (1999). Cerca con Google

Sampath, D., Rao, V. A. & Plunkett, W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22, 9063-9074 (2003). Cerca con Google

Kharbanda, S. et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386, 732-735 (1997). Cerca con Google

Yuan, Z. M., Kharbanda, S. & Kufe, D. 1-beta-Darabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells. Biochemistry 34, 4908 (1995). Cerca con Google

Raina, D. et al. Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. Mol. Pharmacol. 61, 1489-1495 (2002). Cerca con Google

Kharbanda, S. et al. c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-beta-D-arabinofuranosylcytosine. J. Biol. Chem. 270, 30278-30281 (1995). Cerca con Google

Kharbanda, S. et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J. Biol. Chem. 275, 322-327 (2000). Cerca con Google

Sampath, D. & Plunkett, W. The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Res. 60, 6408-6415 (2000). Cerca con Google

Chauhan, D. et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 278, 17593-17596 (2003). Cerca con Google

Buschmann, T. et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell Biol. 21, 2743-2754 (2001). Cerca con Google

Huang, P. & Plunkett, W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol. 36, 181-188 (1995). Cerca con Google

Komatsu, K. et al. Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nat. Cell Biol. 2, 1-6 (2000). Cerca con Google

Yoshida, K., Komatsu, K., Wang, H. G. & Kufe, D. c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage. Mol. Cell Biol. 22, 3292-3300 (2002). Cerca con Google

Ritzel, M. W. et al. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol. Membr. Biol. 18, 65-72 (2001). Cerca con Google

Mackey, J. R. et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J. Natl. Cancer Inst. 91, 1876-1881 (1999). Cerca con Google

Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002). Cerca con Google

Grant, C. E. et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54, 357-361 (1994). Cerca con Google

Endicott, J. A. & Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58, 137-171 (1989). Cerca con Google

Michael, M. & Doherty, M. M. Tumoral drug metabolism: overview and its implications for cancer therapy. J. Clin. Oncol. 23, 205-229 (2005). Cerca con Google

Igney, F. H. & Krammer, P. H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277-288 (2002). Cerca con Google

Rathmell, J. C. & Thompson, C. B. The central effectors of cell death in the immune system. Annu. Rev. Immunol. 17, 781-828 (1999). Cerca con Google

Holcik, M. & Sonenberg, N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 6, 318-327 (2005). Cerca con Google

Gebauer, F. & Hentze, M. W. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell Biol. 5, 827-835 (2004). Cerca con Google

Gingras, A. C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N. & Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12, 502-513 (1998). Cerca con Google

Flynn, A. & Proud, C. G. The role of eIF4 in cell proliferation. Cancer Surv. 27, 293-310 (1996). Cerca con Google

Ruggero, D. & Pandolfi, P. P. Does the ribosome translate cancer? Nat. Rev. Cancer 3, 179-192 (2003). Cerca con Google

Tee, A. R. & Proud, C. G. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 19, 3021-3031 (2000). Cerca con Google

Rousseau, D., Kaspar, R., Rosenwald, I., Gehrke, L. & Sonenberg, N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. U. S. A 93, 1065-1070 (1996). Cerca con Google

Lazaris-Karatzas, A., Montine, K. S. & Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 345, 544-547 (1990). Cerca con Google

Johannes, G., Carter, M. S., Eisen, M. B., Brown, P. O. & Sarnow, P. Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. Proc. Natl. Acad. Sci. U. S. A 96, 13118-13123 (1999). Cerca con Google

Hellen, C. U. & Sarnow, P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. 15, 1593-1612 (2001). Cerca con Google

Johannes, G. & Sarnow, P. Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. RNA. 4, 1500-1513 (1998). Cerca con Google

Wolin, S. L. & Cedervall, T. The La protein. Annu. Rev. Biochem. 71, 375-403 (2002). Cerca con Google

Holcik, M. & Korneluk, R. G. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation. Mol. Cell Biol. 20, 4648-4657 (2000). Cerca con Google

Holcik, M., Yeh, C., Korneluk, R. G. & Chow, T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19, 4174-4177 (2000). Cerca con Google

Dever, T. E. et al. Phosphorylation of initiation factor 2 alpha by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast. Cell 68, 585-596 (1992). Cerca con Google

Clemens, M. J. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 23, 3180-3188 (2004). Cerca con Google

Terada, N. et al. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. U. S. A 91, 11477-11481 (1994). Cerca con Google

Jefferies, H. B. et al. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 16, 3693-3704 (1997). Cerca con Google

Meyuhas, O. Synthesis of the translational apparatus is regulated at the translational level. Eur. J. Biochem. 267, 6321-6330 (2000). Cerca con Google

Myers, S. M., Eng, C., Ponder, B. A. & Mulligan, L. M. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 11, 2039-2045 (1995). Cerca con Google

De, B. A. & Rhoads, R. E. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc. Natl. Acad. Sci. U. S. A 87, 8212-8216 (1990). Cerca con Google

Miyagi, Y. et al. Elevated levels of eukaryotic translation initiation factor eIF-4E, mRNA in a broad spectrum of transformed cell lines. Cancer Lett. 91, 247-252 (1995). Cerca con Google

Fukuchi-Shimogori, T. et al. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 57, 5041-5044 (1997). Cerca con Google

Barlund, M. et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 92, 1252-1259 (2000). Cerca con Google

Darveau, A., Pelletier, J. & Sonenberg, N. Differential efficiencies of in vitro translation of mouse c-myc transcripts differing in the 5' untranslated region. Proc. Natl. Acad. Sci. U. S. A 82, 2315-2319 (1985). Cerca con Google

Ruggero, D. et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 299, 259-262 (2003). Cerca con Google

Heiss, N. S. et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19, 32-38 (1998). Cerca con Google

Draptchinskaia, N. et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat. Genet. 21, 169-175 (1999). Cerca con Google

Dinney, C. P. et al. Focus on bladder cancer. Cancer Cell 6, 111-116 (2004). Cerca con Google

Hertel, L. W. et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 50, 4417-4422 (1990). Cerca con Google

Abratt, R. P. et al. Efficacy and safety profile of gemcitabine in non-smallcell lung cancer: a phase II study. J. Clin. Oncol. 12, 1535-1540 (1994). Cerca con Google

van Moorsel, C. J., Peters, G. J. & Pinedo, H. M. Gemcitabine: Future Prospects of Single-Agent and Combination Studies. Oncologist. 2, 127-134 (1997). Cerca con Google

Bergman, A. M., Pinedo, H. M. & Peters, G. J. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. 5, 19-33 (2002). Cerca con Google

Heinemann, V., Hertel, L. W., Grindey, G. B. & Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 48, 4024-4031 (1988). Cerca con Google

Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B. & Plunkett, W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51, 6110-6117 (1991). Cerca con Google

Shi, Z. et al. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res. 61, 1065-1072 (2001). Cerca con Google

Kroep, J. R. et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br. J. Cancer 83, 1069-1076 (2000). Cerca con Google

van Moorsel, C. J. et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer 80, 981-990 (1999). Cerca con Google

Bouffard, D. Y., Laliberte, J. & Momparler, R. L. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol. 45, 1857-1861 (1993). Cerca con Google

Heinemann, V. et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res. 52, 533-539 (1992). Cerca con Google

Carmichael, J. The role of gemcitabine in the treatment of other tumours. Br. J. Cancer 78 Suppl 3, 21-25 (1998). Cerca con Google

Ruiz, v. H., V et al. Development and molecular characterization of a 2',2'- difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54, 4138-4143 (1994). Cerca con Google

Shewach, D. S., Reynolds, K. K. & Hertel, L. Nucleotide specificity of human deoxycytidine kinase. Mol. Pharmacol. 42, 518-524 (1992). Cerca con Google

Datta, N. S., Shewach, D. S., Hurley, M. C., Mitchell, B. S. & Fox, I. H. Human T-lymphoblast deoxycytidine kinase: purification and properties. Biochemistry 28, 114-123 (1989). Cerca con Google

Smid, K., van Moorsel, C. J., Noordhuis, P., Voorn, D. A. & Peters, G. J. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Int. J. Oncol. 19, 157-162 (2001). Cerca con Google

Plunkett, W. et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22, 3-10 (1995). Cerca con Google

Grant, S. Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. 72, 197-233 (1998). Cerca con Google

Pourquier, P. et al. Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc. Natl. Acad. Sci. U. S. A 97, 1885-1890 (2000). Cerca con Google

Dumontet, C. et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. 106, 78-85 (1999). Cerca con Google

Bergman, A. M. et al. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur. J. Cancer 36, 1974-1983 (2000) Cerca con Google

Solo per lo Staff dell Archivio: Modifica questo record